Shenzhen Mindray Bio-Medical Electronics (300760.CH) - The Logic Behind Optimism
221 Views19 Oct 2021 08:51
The article analyzed Mindray in terms of the core businesses, the 2021H1 performance, the impact of centralized procurement, the Hytest deal, the comparison with Hengrui and MIcroport and the outlook.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- Micro-Tech Nanjing (688029.CH) - Potential for Reversals Despite Short-Term Pressure on Performance28 Jul 2022
- Shenzhen Mindray Bio-Medical Electronics (300760.CH) - Still a “Safe Play” Despite Growth Slowdown03 May 2022
- Jafron Biomedical (300529.CH) - Logic Changes Due to The Centralized Procurement16 Nov 2021
- Shenzhen Mindray Bio-Medical Electronics (300760.CH) - The Logic Behind Optimism19 Oct 2021
- Microport Scientific (853.HK) - The Favorable and the Unfavorable Aspects11 Oct 2021
- Microport Scientific (853.HK) - It Is a Good Time to See Some Concerns17 May 2021
- Shenzhen Mindray Bio-Medical Electronics - The Future Performance Is Worth Looking Forward To10 May 2021
x